Shrikanth A.G. Reddy

1.8k total citations
23 papers, 1.6k citations indexed

About

Shrikanth A.G. Reddy is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Shrikanth A.G. Reddy has authored 23 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 8 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Shrikanth A.G. Reddy's work include PI3K/AKT/mTOR signaling in cancer (10 papers), Immune Response and Inflammation (4 papers) and NF-κB Signaling Pathways (4 papers). Shrikanth A.G. Reddy is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (10 papers), Immune Response and Inflammation (4 papers) and NF-κB Signaling Pathways (4 papers). Shrikanth A.G. Reddy collaborates with scholars based in United States, Australia and Singapore. Shrikanth A.G. Reddy's co-authors include Warren S.‐L. Liao, Jianyi H. Huang, Bharat B. Aggarwal, James L. Abbruzzese, Yixin Yao, Takayuki Asano, Donghui Li, Jijiang Zhu, David G. Menter and W.K. Alfred Yung and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Immunology and Cancer Research.

In The Last Decade

Shrikanth A.G. Reddy

23 papers receiving 1.5k citations

Peers

Countries citing papers authored by Shrikanth A.G. Reddy

Since Specialization

Citations

This map shows the geographic impact of Shrikanth A.G. Reddy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shrikanth A.G. Reddy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shrikanth A.G. Reddy more than expected).

Fields of papers citing papers by Shrikanth A.G. Reddy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shrikanth A.G. Reddy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shrikanth A.G. Reddy. The network helps show where Shrikanth A.G. Reddy may publish in the future.

Co-authorship network of co-authors of Shrikanth A.G. Reddy

This figure shows the co-authorship network connecting the top 25 collaborators of Shrikanth A.G. Reddy. A scholar is included among the top collaborators of Shrikanth A.G. Reddy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shrikanth A.G. Reddy. Shrikanth A.G. Reddy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway 2011 ·Free Radical Biology and Medicine ·(unknown), Victoria Palau, Janet Lightner, (unknown), William L. Stone, Sharon Campbell, Shrikanth A.G. Reddy, Koyamangalath Krishnan	70
2	Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies 2010 ·BMC Cancer ·Milind Javle, Rachna T. Shroff, Henry Xiong, Gauri Varadhachary, David R. Fogelman, Shrikanth A.G. Reddy, Darren W. Davis, Yujian Zhang, Robert A. Wolff, James L. Abbruzzese	141
3	Activator Protein-1 Has an Essential Role in Pancreatic Cancer Cells and Is Regulated by a Novel Akt-Mediated Mechanism 2009 ·Molecular Cancer Research ·(unknown), Takayuki Asano, Yixin Yao, Ronghua Zhang, François-Xavier Claret, Murray Korc, Kanaga Sabapathy, David G. Menter, James L. Abbruzzese, Shrikanth A.G. Reddy	21
4	Constitutive activation of AKT pathway inhibits TNF-induced apoptosis in mitochondrial DNA-deficient human myelogenous leukemia ML-1a 2008 ·Cancer Letters ·Seigo Suzuki, Akihiro Naito, Takayuki Asano, Teresa Evans, Shrikanth A.G. Reddy, Masahiro Higuchi	15
5	Establishment of three-dimensional cultures of human pancreatic duct epithelial cells 2007 ·Biochemical and Biophysical Research Communications ·Angelica M. Gutierrez‐Barrera, David G. Menter, James L. Abbruzzese, Shrikanth A.G. Reddy	34
6	PTEN down regulates AP-1 and targets c-fos in human glioma cells Via PI3-kinase/Akt pathway 2007 ·Molecular and Cellular Biochemistry ·Dimpy Koul, Ruijun Shen, Shishir Shishodia, (unknown), Krishna Bhat, Shrikanth A.G. Reddy, Bharat B. Aggarwal, W.K. Alfred Yung	29
7	Role of the PI3K/Akt pathway in promoting drug resistance of human pancreatic cells 2006 ·Cancer Research ·Ellis W.T. Wong, Shrikanth A.G. Reddy, José Rubén García-Sánchez, James A. McCubrey	1
8	Hypothesis Generation in Signaling Networks 2006 ·Journal of Computational Biology ·Derek Ruths, Luay Nakhleh, M. Sriram Iyengar, Shrikanth A.G. Reddy, Prahlad T. Ram	18
9	The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation 2005 ·Biochemical and Biophysical Research Communications ·Takayuki Asano, Yixin Yao, Jijiang Zhu, Donghui Li, James L. Abbruzzese, Shrikanth A.G. Reddy	57
10	The IL-1 receptor accessory protein is essential for PI 3-kinase recruitment and activation 2004 ·Biochemical and Biophysical Research Communications ·Shrikanth A.G. Reddy, Yu‐Feng Lin, Helen J. Huang, Ajoy K. Samanta, Warren S.‐L. Liao	12
11	The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells 2004 ·Oncogene ·Takayuki Asano, Yixin Yao, Jijiang Zhu, Donghui Li, James L. Abbruzzese, Shrikanth A.G. Reddy	247
12	Alleviating the Suppression of Glycogen Synthase Kinase-3β by Akt Leads to the Phosphorylation of cAMP-response Element-binding Protein and Its Transactivation in Intact Cell Nuclei 2003 ·Journal of Biological Chemistry ·(unknown), Shrikanth A.G. Reddy, John L. Clifford, Roger J. Davis, Akira Kikuchi, Scott M. Lippman, David G. Menter	60
13	Resistance of Human Ovarian Cancer Cells to Tumor Necrosis Factor α Is a Consequence of Nuclear Factor κB-Mediated Induction of Fas-Associated Death Domain-Like Interleukin-1β-Converting Enzyme-Like Inhibitory Protein 2003 ·Endocrinology ·Chao Xiao, Xiaojuan Yan, Yulian Li, Shrikanth A.G. Reddy, Benjamin K. Tsang	50
14	Tumor Suppressor MMAC/PTEN Inhibits Cytokine-induced NFκB Activation without Interfering with the IκB Degradation Pathway 2001 ·Journal of Biological Chemistry ·Dimpy Koul, Yixin Yao, James L. Abbruzzese, W.K. Alfred Yung, Shrikanth A.G. Reddy	76
15	Phosphatidylinositol 3-Kinase as a Mediator of TNF-Induced NF-κB Activation 2000 ·The Journal of Immunology ·Shrikanth A.G. Reddy, Jianyi H. Huang, Warren S.‐L. Liao	161
16	Purification and Characterization of the Serum Amyloid A3 Enhancer Factor 1999 ·Journal of Biological Chemistry ·Zhanyong Bing, Shrikanth A.G. Reddy, (unknown), Warren S.‐L. Liao, Jun Qin	37
17	Purification and Identification of a Tissue-specific Repressor Involved in Serum Amyloid A1 Gene Expression 1999 ·Journal of Biological Chemistry ·(unknown), Shrikanth A.G. Reddy, Warren S.‐L. Liao	8
18	Phosphatidylinositol 3-Kinase in Interleukin 1 Signaling 1997 ·Journal of Biological Chemistry ·Shrikanth A.G. Reddy, Jianyi H. Huang, Warren S.‐L. Liao	217
19	Curcumin is a non‐competitive and selective inhibitor of phosphorylase kinase 1994 ·FEBS Letters ·Shrikanth A.G. Reddy, Bharat B. Aggarwal	193
20	Purification and properties of a protamine kinase from bovine kidney microsomes 1992 ·Archives of Biochemistry and Biophysics ·(unknown), Shrikanth A.G. Reddy, Zahi Damuni	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact